YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Five Reasons Illumina Should Stay Independent


March 6, 2012 | The Illumina-Roche acquisition dance continues and Luke Timmerman at Xconomy says that if the low-ball takeover happens, it would be, "bad for Illumina shareholders, bad for the genetic tools industry, bad for science, bad for the San Diego innovation community, and bad for the personalized medicine movement." He calls for a rejection of Roche's offer. Xconomy
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.